Anne Langsted Selected Research

Anne Langsted Research Topics

Disease

26	Cardiovascular Diseases (Cardiovascular Disease) 02/2024 - 11/2016
20	Myocardial Infarction 01/2023 - 05/2014
10	Aortic Valve Stenosis (Aortic Stenosis) 01/2022 - 07/2015
7	Pancreatitis 10/2023 - 07/2016
7	Myocardial Ischemia (Ischemic Heart Diseases) 01/2023 - 05/2014
6	Atherosclerosis 01/2020 - 07/2016
5	Inflammation (Inflammations) 01/2023 - 05/2014
5	Ischemic Stroke 01/2023 - 01/2019
4	Hypertriglyceridemia 10/2023 - 01/2018
4	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 11/2022 - 07/2016
3	Diabetes Mellitus 01/2023 - 03/2011
2	Chronic Pancreatitis 01/2023 - 09/2021
2	Cholelithiasis 01/2023 - 12/2016
2	Thrombosis (Thrombus) 01/2022 - 11/2016
2	Hypertension (High Blood Pressure) 01/2019 - 12/2016
1	Hypoglycemia (Reactive Hypoglycemia) 04/2024
1	Peripheral Arterial Disease 01/2023
1	COVID-19 01/2022
1	Heart Failure 01/2022
1	Aortic Valve Disease 01/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 09/2021
1	Neoplasms (Cancer) 01/2021
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Infections 01/2021
1	Heart Diseases (Heart Disease) 02/2019
1	Hypercholesterolemia 01/2019
1	Stroke (Strokes) 01/2019
1	Coronary Disease (Coronary Heart Disease) 01/2018
1	Injection Site Reaction 01/2018
1	Macular Degeneration (Age-Related Maculopathy) 12/2017
1	Type 2 Diabetes Mellitus (MODY) 12/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 12/2017
1	beta-Thalassemia (Cooley's Anemia) 12/2017
1	Hemorrhage 11/2017
1	Leukocytosis (Pleocytosis) 01/2017
1	Hyperlipoproteinemia Type III (Broad Beta Disease) 01/2017
1	Pathologic Constriction (Stenosis) 11/2016
1	Homozygous Familial Hypercholesterolemia 07/2016

Drug/Important Bio-Agent (IBA)

28	Lipoprotein(a)IBA 02/2024 - 05/2014
19	CholesterolIBA 11/2023 - 01/2016
19	LDL CholesterolIBA 01/2023 - 01/2016
15	Triglycerides (Triacylglycerol)IBA 10/2023 - 07/2016
12	LipidsIBA 04/2024 - 03/2011
12	Lipoproteins (Lipoprotein)IBA 11/2023 - 03/2011
7	oxidized low density lipoproteinIBA 01/2023 - 12/2017
7	HDL CholesterolIBA 01/2022 - 01/2018
6	ApolipoproteinsIBA 01/2022 - 03/2011
5	Apolipoproteins B (ApoB)IBA 01/2022 - 01/2018
4	C-Reactive ProteinIBA 01/2023 - 07/2015
4	LDL Lipoproteins (beta Lipoproteins)IBA 01/2023 - 01/2016
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 12/2016
2	VLDL LipoproteinsIBA 10/2023 - 12/2020
2	Antisense OligonucleotidesIBA 01/2021 - 01/2019
2	PCSK9 InhibitorsIBA 01/2019 - 01/2016
1	AngiopoietinsIBA 10/2023
1	ChylomicronsIBA 10/2023
1	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 10/2023
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	HDL LipoproteinsIBA 01/2022
1	fibrin fragment D (D-dimer)IBA 01/2022
1	ProcalcitoninIBA 01/2022
1	eicosapentaenoic acid ethyl esterIBA 12/2021
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 12/2021
1	OilsIBA 12/2021
1	Amylases FDA Link 09/2021
1	VLDL CholesterolIBA 12/2020
1	lipoprotein cholesterolIBA 12/2020
1	Niacin (Nicotinic Acid)FDA LinkGeneric 01/2019
1	AKCEA-APO(a)-LRxIBA 01/2019
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2017
1	Apolipoproteins AIBA 11/2016
1	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 01/2016
1	SubtilisinIBA 01/2016
1	AlbuminsIBA 03/2011

Therapy/Procedure

7	Therapeutics 01/2021 - 01/2017
2	Secondary Prevention 01/2023 - 01/2020
1	Injections 01/2018